Ultrasmall Polyphenol-NAD+ Nanoparticle-Mediated Renal Delivery for Mitochondrial Repair and Anti-Inflammatory Treatment of AKI-to-CKD Progression

Ultrasmall Polyphenol-NAD+ Nanoparticle-Mediated Renal Delivery for Mitochondrial Repair and Anti-Inflammatory Treatment of AKI-to-CKD Progression

© 2024 Wiley‐VCH GmbH.

Détails bibliographiques
Publié dans:Advanced materials (Deerfield Beach, Fla.). - 1998. - 36(2024), 30 vom: 31. Juli, Seite e2310731
Auteur principal: Kong, Ying (Auteur)
Autres auteurs: Chen, Xu, Liu, Feng, Tang, Jiageng, Zhang, Yijing, Zhang, Xiangxiang, Zhang, Luyao, Zhang, Tong, Wang, Yaqi, Su, Mengxiao, Zhang, Qixin, Chen, Hanxiang, Zhou, Di, Yi, Fan, Liu, Hong, Fu, Yi
Format: Article en ligne
Langue:English
Publié: 2024
Accès à la collection:Advanced materials (Deerfield Beach, Fla.)
Sujets:Journal Article acute kidney injury chronic kidney disease inflammation mitochondria nanoparticle nicotinamide adenine dinucleotide NAD 0U46U6E8UK Polyphenols plus... Anti-Inflammatory Agents Gallic Acid 632XD903SP
Description
Résumé:© 2024 Wiley‐VCH GmbH.
As a central metabolic molecule, nicotinamide adenine dinucleotide (NAD+) can potentially treat acute kidney injury (AKI) and chronic kidney disease (CKD); however, its bioavailability is poor due to short half-life, instability, the deficiency of targeting, and difficulties in transmembrane transport. Here a physiologically adaptive gallic acid-NAD+ nanoparticle is designed, which has ultrasmall size and pH-responsiveness, passes through the glomerular filtration membrane to reach injured renal tubules, and efficiently delivers NAD+ into the kidneys. With an effective accumulation in the kidneys, it restores renal function, immune microenvironment homeostasis, and mitochondrial homeostasis of AKI mice via the NAD+-Sirtuin-1 axis, and exerts strong antifibrotic effects on the AKI-to-CKD transition by inhibiting TGF-β signaling. It also exhibits excellent stability, biodegradable, and biocompatible properties, ensuring its long-term safety, practicality, and clinical translational feasibility. The present study shows a potential modality of mitochondrial repair and immunomodulation through nanoagents for the efficient and safe treatment of AKI and CKD
Description:Date Completed 25.07.2024
Date Revised 25.07.2024
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-4095
DOI:10.1002/adma.202310731